EBR Systems (ASX:EBR) submitted its application to the US Centers for Medicare & Medicaid Services for the transitional pass-through reimbursement scheme for its WiSE cardiac resynchronization therapy system, according to a Monday filing with the Australian bourse.
The reimbursement program aims to facilitate hospital adoption of medical technologies that demonstrate substantial clinical improvement for patients but are not yet fully incorporated into standard Medicare payment rates, the filing said.
The program is expected to be effective from Oct. 1, according to the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。